📊 CSBR Key Takeaways
Investment Thesis
Champions Oncology shows concerning financial deterioration with negative operating cash flow of -2.5M and free cash flow of -2.8M despite 13.5% revenue growth, indicating the company is burning cash and unable to convert sales into profits. The company is unprofitable with a -1.1% net margin and negative ROE of -11.9%, while maintaining a precarious liquidity position with a current ratio of 0.98x that leaves minimal margin for error.
CSBR Strengths
- Revenue growth of 13.5% YoY demonstrates demand for services
- Cash position of 7.1M provides near-term operational runway
- Low debt burden with 0.00x debt-to-equity ratio reduces financial risk
CSBR Risks
- Negative operating cash flow of -2.5M indicates unsustainable cash burn despite positive revenue growth
- Current ratio of 0.98x signals liquidity pressure with current liabilities exceeding current assets
- Persistent unprofitability with operating margin of -1.4% and net margin of -1.1% raises questions about business model viability
- Free cash flow margin of -6.1% shows company is consuming capital to generate each dollar of revenue
- Stockholders' equity of only 4.3M on total assets of 28.4M indicates thin equity cushion relative to liabilities
Key Metrics to Watch
- Operating cash flow trend and path to positive FCF generation
- Gross margin expansion and operating leverage as revenue scales
- Current ratio maintenance above 1.0x to ensure adequate liquidity
- Net income improvement trajectory and timeline to sustained profitability
CSBR Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CSBR Profitability Ratios
CSBR vs Healthcare Sector
How CHAMPIONS ONCOLOGY, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CSBR Balance Sheet & Liquidity
CSBR 5-Year Financial Trend
5-Year Trend Summary: CHAMPIONS ONCOLOGY, INC.'s revenue has grown significantly by 39% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.54 indicates the company is currently unprofitable.
CSBR Growth Metrics (YoY)
CSBR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $16.6M | -$279.0K | $-0.02 |
| Q2 2026 | $13.5M | -$169.0K | $-0.01 |
| Q1 2026 | $14.0M | -$436.0K | $-0.03 |
| Q3 2025 | $12.0M | $728.0K | $-0.19 |
| Q2 2025 | $11.6M | $728.0K | $0.05 |
| Q1 2025 | $12.6M | $1.3M | $0.09 |
| Q3 2024 | $12.0M | -$16.0K | $-0.18 |
| Q2 2024 | $11.6M | -$16.0K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CSBR Capital Allocation
CSBR SEC Filings
Access official SEC EDGAR filings for CHAMPIONS ONCOLOGY, INC. (CIK: 0000771856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CSBR
What is the AI rating for CSBR?
CHAMPIONS ONCOLOGY, INC. (CSBR) has an AI rating of SELL with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CSBR's key strengths?
Revenue growth of 13.5% YoY demonstrates demand for services. Cash position of 7.1M provides near-term operational runway.
What are the risks of investing in CSBR?
Negative operating cash flow of -2.5M indicates unsustainable cash burn despite positive revenue growth. Current ratio of 0.98x signals liquidity pressure with current liabilities exceeding current assets.
What is CSBR's revenue and growth?
CHAMPIONS ONCOLOGY, INC. reported revenue of $45.6M.
Does CSBR pay dividends?
CHAMPIONS ONCOLOGY, INC. does not currently pay dividends.
Where can I find CSBR SEC filings?
Official SEC filings for CHAMPIONS ONCOLOGY, INC. (CIK: 0000771856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CSBR's EPS?
CHAMPIONS ONCOLOGY, INC. has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.